Search results for "Activated prothrombin complex concentrate"

showing 3 items of 3 documents

Activated prothrombin complex concentrate (FEIBA® ) in acquired haemophilia A: a large multicentre Italian study - the FAIR Registry

2019

MalePediatricsmedicine.medical_specialtyhaemophiliacoagulation factors030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineAcquired haemophiliaHumansMedicinecoagulation factorProspective StudiesRegistriesProspective cohort studyActivated prothrombin complex concentrateRetrospective Studiesbleeding disorders; coagulation factors; factor VIII; haemophilia; Blood Coagulation Factors; Female; Hemophilia A; Humans; Italy; Male; Prospective Studies; Retrospective Studies; Registriesbleeding disordersbleeding disorderbusiness.industryRetrospective cohort studyHematologymedicine.diseaseBlood Coagulation FactorsItalyfactor VIIIFemalebusiness030215 immunologyBritish Journal of Haematology
researchProduct

Low dose of aPCC after the initial treatment in acquired haemophilia A is useful to reduce bleeding relapses: Data from the FAIR registry

2019

Background: Bypassing agents are the first line therapy in patients with acquired haemophilia A (AHA). Activated prothrombin complex concentrate (aPCC) proved to be effective as initial treatment, but 20% of patients (pts) had relapses. aPCC as short-term prophylaxis to reduce subsequent bleeds is still not clear. Aim: To evaluate whether a short-term prophylaxis with low dose of aPCC can reduce bleeding relapses after initial AHA treatment, maintaining safety. Methods: The FAIR Registry is a retrospective-prospective study started on December 2012, that collected data on all pts with AHA treated with aPCC in 12 Italian Haemophilia Centers. All statistical analyses were carried out in the 5…

Malemedicine.medical_specialtyAcquired haemophilia; Bleeding relapses; Bypassing agents; Prophylaxis; Aged; Female; Hemophilia A; Hemorrhage; Humans; Male; Prospective Studies; Recombinant Proteins; Recurrence; Retrospective StudiesHemorrhage030204 cardiovascular system & hematologyHemophilia AHaemophilia03 medical and health sciences0302 clinical medicineFirst line therapyRecurrenceInternal medicineAcquired haemophiliamedicineHumansInitial treatmentIn patientProspective StudiesProphylaxiActivated prothrombin complex concentrateBypassing agentAgedRetrospective StudiesHematologyProphylaxisbusiness.industryLow doseBleeding relapseHematologymedicine.diseaseRecombinant Proteins030220 oncology & carcinogenesisFemaleBleeding relapsesBypassing agentsbusinessAcquired haemophiliaThrombosis Research
researchProduct

Combined use of antifibrinolytics and activated prothrombin complex concentrate (aPCC) is not related to thromboembolic events in patients with acqui…

2019

Antifibrinolytics combined with aPCC are not routinely administered to patients with acquired hemophilia A due to increased thrombotic risk. This association normalizes clot stability, and improves the efficacy of therapy, but can increase the risk of severe side effects. Due to these premises it has always raised doubts and perplexities in the clinics. We now report the data of the "FEIBA® on acquired haemophilia A Italian Registry (FAIR Registry)", a retrospective-prospective study that included 56 patients. This is the first study that assessed the clinical response of the combination of aPCC and antifibrinolytic agents in patients with acquired haemophilia A. A total of 101 acute bleeds…

medicine.medical_specialtyAntifibrinolyticmedicine.drug_classHemorrhage030204 cardiovascular system & hematologyHemophilia APremises03 medical and health sciences0302 clinical medicineDrug TherapyThromboembolismAntifibrinolytic agentInternal medicineActivated prothrombin complex concentrateAcquired haemophiliaThromboembolic riskHumansMedicineIn patientRegistries030212 general & internal medicineAcquired haemophilia AHematologybusiness.industryHematologyAcquired haemophilia A; Activated prothrombin complex concentrate; Antifibrinolytics; Thromboembolic risk; Antifibrinolytic Agents; Blood Coagulation Factors; Cardiovascular Diseases; Drug Therapy Combination; Hemophilia A; Hemorrhage; Humans; Registries; ThromboembolismAntifibrinolytic AgentsBlood Coagulation FactorsClinical trialTolerabilityCardiovascular DiseasesCombinationAntifibrinolyticDrug Therapy CombinationAntifibrinolyticsCardiology and Cardiovascular Medicinebusiness
researchProduct